<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635530</url>
  </required_header>
  <id_info>
    <org_study_id>T1/2012</org_study_id>
    <nct_id>NCT01635530</nct_id>
  </id_info>
  <brief_title>Study of Lyme Neuroborreliosis</brief_title>
  <official_title>Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether four weeks treatment with oral
      doxycycline is as effective as three weeks treatment with intravenous ceftriaxone in patients
      with Lyme neuroborreliosis. The other purpose is to improve laboratory diagnostics of Lyme
      neuroborreliosis and further define the manifestations and epidemiology of the disease in
      Finland.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The condition of study subjects</measure>
    <time_frame>12 months</time_frame>
    <description>The condition of study subjects will be measured with scale (including numbers 0-10) before the treatment with antibiotic, 4 months and 12 months after the treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lyme Neuroborreliosis</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of intravenous ceftriaxone (2 g/day), three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with oral doxycycline (200mg / day), four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline: 100mg tablet two times per day, four weeks</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>2 g intravenous once a day, three weeks</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with typical clinical manifestations of Lyme neuroborreliosis and intrathecal
             antibody production against Borrelia burgdorferi

          -  patients with typical clinical manifestations of Lyme neuroborreliosis and erythema
             migrans within three months

          -  patients with some clinical manifestations of Lyme neuroborreliosis and presence of
             antibodies against Borrelia burgdorferi bacteria in blood.

        Exclusion Criteria:

          -  pregnancy

          -  lactation

          -  use of any antibiotics two weeks before study treatments begins

          -  an allergy to ceftriaxone or doxycycline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jarmo Oksi, vs. prof.</last_name>
    <phone>+35823130786</phone>
    <email>jarmo.oksi@utu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mari Kanerva</last_name>
      <phone>+258941775930</phone>
      <email>mari.kanerva@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Mari Kanerva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Kortela</last_name>
      <phone>+35823130098</phone>
      <email>elilam@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Jarmo Oksi, vs. prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Kortela</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jukka Hyt√∂nen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Jarmo Oksi</investigator_full_name>
    <investigator_title>vs.prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Neuroborreliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

